Federated Hermes’s Jasper Therapeutics JSPR Stock Holding History

Federated Hermes’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$80	Sell	189 -3,679	-95%	-$2.75K	﹤0.01%	2034
2026 Q1	$3.39K	Sell	3,868 -1,079	-22%	-$1.5K	﹤0.01%	1931
2025 Q4	$9.05K	Buy	4,947 +2,150	+77%	+$4.32K	﹤0.01%	1841
2025 Q3	$6.66K	Buy	2,797 +820	+41%	+$2.49K	﹤0.01%	1915
2025 Q2	$11K	Buy	1,977 +920	+87%	+$4.53K	﹤0.01%	1807
2025 Q1	$4.54K	Buy	+1,057	New	+$7.03K	﹤0.01%	1884
2022 Q2	–	Sell	-25,170	Closed	-$894K	–	2224
2022 Q1	$894K	Sell	25,170 -95,488	-79%	-$4.3M	﹤0.01%	1288
2021 Q4	$9.47M	Sell	120,658 -29,342	-20%	-$2.75M	0.02%	661
2021 Q3	$12.5M	Buy	+150,000	New	+$15.3M	0.02%	593

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's JSPR Position: Q2 2026 in Review

Federated Hermes reduced its Jasper Therapeutics (JSPR) stake by 95% in Q2 2026, selling an estimated $2.75K and leaving 189 shares worth $80. The position accounts for ﹤0.01% of the portfolio, ranked #2034.

Federated Hermes first reported a position in JSPR in Q3 2021 and has held it in 9 quarters since. The position peaked at $12.5M in Q3 2021. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Federated Hermes held 189 shares of Jasper Therapeutics worth $80 as of Q2 2026.
Federated Hermes sold 3,679 Jasper Therapeutics shares in Q2 2026, an estimated $2.75K.
Jasper Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #2034 holding.
Federated Hermes first reported a position in Jasper Therapeutics in Q3 2021 and has held it in 9 quarters since.
Federated Hermes's Jasper Therapeutics position peaked at $12.5M in Q3 2021.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.